GCA
CRL icon

Gideon Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Gideon Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,670
Closed -$243K – 305
2019
Q1 		$243K Sell
1,670
-2,520
-60% -$331K 0.09% 320
2018
Q4 		$474K Buy
+4,190
New +$525K 0.19% 164

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Gideon Capital Advisors's CRL Position: Q2 2019 in Review

Gideon Capital Advisors sold out of Charles River Laboratories (CRL) in Q2 2019, closing a stake of 1,670 shares — an estimated $243K sold.

Gideon Capital Advisors first reported a position in CRL in Q4 2018 and held it in 2 quarters. The position peaked at $474K in Q4 2018. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

  • Gideon Capital Advisors reported no remaining Charles River Laboratories position as of Q2 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 1,670 Charles River Laboratories shares in Q2 2019, an estimated $243K.
  • Gideon Capital Advisors first reported a position in Charles River Laboratories in Q4 2018 and held it in 2 quarters.
  • Gideon Capital Advisors's Charles River Laboratories position peaked at $474K in Q4 2018.
  • 405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.